Earnings summaries and quarterly performance for Apellis Pharmaceuticals.
Executive leadership at Apellis Pharmaceuticals.
Cedric Francois
Detailed
Chief Executive Officer
CEO
CB
Caroline Baumal
Detailed
Chief Medical Officer
DA
David Acheson
Detailed
Executive Vice President, Commercial
DW
David Watson
Detailed
General Counsel and Secretary
JC
Jim Chopas
Detailed
Vice President, Corporate Controller and Chief Accounting Officer
MD
Mark DeLong
Detailed
Chief Business & Strategy Officer
NN
Nur Nicholson
Detailed
Chief Technical Operations Officer
PD
Pascal Deschatelets
Detailed
Chief Scientific Officer
TS
Timothy Sullivan
Detailed
Chief Financial Officer and Treasurer
Board of directors at Apellis Pharmaceuticals.
Research analysts who have asked questions during Apellis Pharmaceuticals earnings calls.
Annabel Samimy
Stifel Financial Corp.
7 questions for APLS
Also covers: ALT, CARA, CLSD +14 more
AR
Anupam Rama
JPMorgan Chase & Co.
7 questions for APLS
Also covers: BBIO, BOLD, CTMX +16 more
DT
Douglas Tsao
H.C. Wainwright & Co.
7 questions for APLS
Also covers: ALKS, ARGX, ARQT +19 more
Jonathan Miller
Evercore ISI
7 questions for APLS
Also covers: ARVN, ATRA, AVIR +8 more
LH
Lachlan Hanbury-Brown
William Blair & Company
7 questions for APLS
Also covers: ARSP, EYEN, HROW +4 more
YN
Yigal Nochomovitz
Citigroup Inc.
7 questions for APLS
Also covers: ALDX, ARCT, ARDX +22 more
Biren Amin
Piper Sandler Companies
6 questions for APLS
Also covers: ALLO, BBIO, CMPX +5 more
Graig Suvannavejh
Mizuho Securities
6 questions for APLS
Also covers: ADAP, ADVM, ALEC +11 more
LW
Lisa Walter
RBC Capital Markets
6 questions for APLS
Also covers: EYPT, OCUL, RGNX +2 more
Ryan Deschner
Raymond James Financial
6 questions for APLS
Also covers: ARDX, ARSP, GLMD +7 more
CK
Colleen Kusy
Robert W. Baird & Co.
5 questions for APLS
Also covers: BPMC, CHRS, EYPT +5 more
Judah Frommer
Morgan Stanley
5 questions for APLS
Also covers: ARQT, ATAI, CMPS +4 more
DR
Divya Rao
TD Cowen
4 questions for APLS
Also covers: AGIO, PBYI, VRTX +1 more
Joe Thomas
Scotiabank
4 questions for APLS
Also covers: OCUL, TVTX
Katherine Wang
Jefferies
4 questions for APLS
Also covers: ALKS, IRWD
Shrunatra Mishra
Goldman Sachs
4 questions for APLS
Also covers: SAGE
Simone Nasroodin
Wells Fargo
4 questions for APLS
Timur Ivannikov
Raymond James
4 questions for APLS
Also covers: GLMD, IFRX, MIRM
Derek Archila
Wells Fargo
3 questions for APLS
Also covers: ARGX, ARVN, ASND +9 more
EM
Eliana Merle
UBS
3 questions for APLS
Also covers: ALNY, ARVN, ARWR +17 more
PN
Philip Nadeau
TD Cowen
3 questions for APLS
Also covers: ADVM, ATRA, BIIB +13 more
Salveen Richter
Goldman Sachs
3 questions for APLS
Also covers: ACAD, AGIO, ALLO +20 more
TA
Tazeen Ahmad
Bank of America
3 questions for APLS
Also covers: ACAD, ALNY, ARGX +20 more
JF
Jasmine Fels
UBS
2 questions for APLS
Also covers: ALT, ARWR, BMRN
Akash Tewari
Jefferies
1 question for APLS
Also covers: ALKS, ARGX, ARVN +15 more
CK
Colin Kosse
Robert W. Baird & Co.
1 question for APLS
GH
Greg Harrison
RBC Capital Markets
1 question for APLS
Also covers: ADCT, BBIO, EDIT +3 more
Gregory Harrison
Scotiabank
1 question for APLS
Also covers: AGIO, EYPT, GERN +3 more
Joseph Stringer
Needham & Company
1 question for APLS
Also covers: CDTX, LXRX, PCVX +3 more
LC
Laura Chico
Wedbush Securities
1 question for APLS
Also covers: ARDX, BCRX, BHVN +11 more
NE
Nicholas Econom
Raymond James
1 question for APLS
Also covers: EDIT, WVE
SS
Steven Seedhouse
Raymond James
1 question for APLS
Also covers: BCRX, EDIT, GLMD +2 more
Recent press releases and 8-K filings for APLS.
Apellis Pharmaceuticals Announces Preliminary Q4 and Full-Year 2025 Financial Results and Strategic Updates
APLS
Earnings
Guidance Update
New Projects/Investments
- Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, with SYFOVRE contributing $587 million and EMPAVELI $102 million.
- As of December 31, 2025, the company held approximately $466 million in cash and cash equivalents, and expects these resources, combined with projected revenues, to fund operations to profitability.
- SYFOVRE maintained its market leadership in geographic atrophy with approximately 60% total market share in Q4 2025 and saw a 17% year-over-year growth in total injection demand.
- EMPAVELI achieved 267 new patient start forms in 2025, reaching over 5% market penetration in C3G and primary IC-MPGN post-launch, and initiated pivotal trials for two new nephrology indications.
2 days ago
Apellis discusses SYFOVRE growth, EMPAVELI launch, and pipeline at JPMorgan Healthcare Conference
APLS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Apellis, a self-funded company, reported that SYFOVRE for geographic atrophy maintains approximately 60% market share with 17% year-over-year injection growth, anticipating renewed growth in 2027 driven by a prefilled syringe (filing in H1 2026) and new functional imaging capabilities.
- The launch of EMPAVELI for C3G and IC-MPGN has achieved over 5% penetration after its first full quarter, with 267 patient start forms, supported by strong efficacy and a safety profile showing zero cases of encapsulated meningococcal infection over 3,000 patient years of dosing.
- Apellis is advancing its pipeline, including APL-3007 for retina with data expected in 2027, Phase III trials for EMPAVELI in FSGS and Delayed Graft Function, and APL-9099, a gene-editing program targeting the FcRn market with an IND planned for H2 2026.
2 days ago
Apellis Provides 2025 Financial Estimates and Updates on Product Performance and Pipeline at J.P. Morgan Healthcare Conference
APLS
Earnings
Guidance Update
New Projects/Investments
- Apellis reported estimated FY 2025 net product revenue of ~$689 million and ~$190 million for Q4 2025, with ~$466 million in cash as of year-end 2025.
- SYFOVRE maintained its market leadership in Geographic Atrophy (GA), achieving estimated ~$587 million in 2025 U.S. net product revenue and announcing 5-year GALE data.
- EMPAVELI secured FDA approval for C3G and primary IC-MPGN, generating estimated ~$102 million in FY 2025 U.S. net product revenue, and initiated pivotal trials for FSGS and DGF.
- The company is advancing its pipeline, including a Phase 2 clinical trial for SYFOVRE + APL-3007 for GA and planning an IND submission for APL-9099 in the second half of 2026.
- Apellis anticipates that existing cash and projected revenues will fund operations to profitability.
2 days ago
Apellis Provides Update on Syfovre, Empaveli, and Pipeline at JPMorgan Healthcare Conference
APLS
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Apellis maintains market leadership in geographic atrophy with Syfovre, holding approximately 60% of the market share and reporting 17% year-over-year injection growth. The company expects renewed growth for Syfovre in 2027, driven by the planned H1 2026 filing of a prefilled syringe and new functional imaging capabilities.
- Empaveli, approved for C3G and primary IC-MPGN, is described as one of the best launches in rare disease nephrology, achieving over 5% penetration after its first full quarter in a U.S. market of approximately 5,000 patients.
- The company is expanding Empaveli's potential with two ongoing Phase III clinical trials for focal segmental glomerulosclerosis (FSGS) and delayed graft function, which could access an additional 30,000 patients.
- Apellis's pipeline includes the APL-9099 gene-editing program, with an Investigational New Drug (IND) application planned for H2 2026, aiming to disrupt the $20 billion FCRN market.
2 days ago
Apellis Pharmaceuticals Highlights Syfovre Market Leadership and Empaveli Launch Success at J.P. Morgan Healthcare Conference
APLS
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Apellis Pharmaceuticals is self-funded and maintains market leadership in geographic atrophy with Syfovre, holding approximately 60% market share and achieving 17% year-over-year injection growth.
- Future growth for Syfovre is anticipated in 2027, primarily driven by the planned launch of a prefilled syringe (filing in H1 2026) and advancements in imaging functional benefits.
- The launch of Empaveli for C3G and IC-MPGN shows strong initial traction, with over 5% penetration and 267 patient start forms after its first full quarter, supported by an "exquisite safety profile".
- Apellis is expanding Empaveli's reach with ongoing Phase III trials in FSGS and delayed graft function, potentially adding 30,000 patients.
- The company's pipeline includes the APL-9099 gene-editing program (IND planned for H2 2026) and the 3007 program for retina, with data expected in 2027.
2 days ago
Apellis Pharmaceuticals Announces Preliminary 2025 Financial Results and Strategic Priorities
APLS
Earnings
Guidance Update
Product Launch
- Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, with SYFOVRE contributing $587 million and EMPAVELI contributing $102 million.
- The company ended 2025 with approximately $466 million in cash and cash equivalents and expects these funds, combined with projected revenues, to be sufficient to fund operations to profitability.
- SYFOVRE experienced 17% year-over-year growth in total injection demand and held approximately 60% total market share in geographic atrophy (GA) in Q4 2025, with a regulatory submission for a prefilled syringe planned for 1H 2026.
- EMPAVELI's launch in C3G and primary IC-MPGN generated 267 new patient start forms in 2025, achieving over 5% market penetration, and pivotal trials were initiated for two additional nephrology indications.
3 days ago
Autolus Therapeutics Presents Positive CARLYSLE Trial Data for Obe-cel in Lupus at ASH 2025
APLS
New Projects/Investments
Product Launch
- Autolus Therapeutics presented preliminary Phase 1 CARLYSLE trial data for obecabtagene autoleucel (obe-cel) in patients with severe refractory systemic lupus erythematosus (srSLE) at the American Society of Hematology (ASH) Annual Meeting on December 8, 2025.
- The data indicated deep, durable responses in the 50 million cell dose level cohort, with 50% of patients achieving CRR and 83% achieving DORIS. All patients demonstrated deep B-cell depletion after infusion, suggesting an immune reset.
- Obe-cel was well tolerated, with no ICANS or high-grade CRS observed, and the 50M dose has been selected as the recommended Phase 2 dose.
- Autolus has aligned with the FDA on a Phase 2 trial design in lupus nephritis (LN) and a potential registrational path, with the LUMINA trial now enrolling.
- Obe-cel, marketed as AUCATZYL®, was FDA-approved in 2024 for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia and received conditional marketing authorization in the UK and EU in 2025.
Dec 8, 2025, 9:05 PM
APLS Provides Updates on Empaveli and Syfovre Launches, Pipeline
APLS
Product Launch
Guidance Update
New Projects/Investments
- The launch of Empaveli for C3G and IC-MPGN is progressing as expected, with 152 new patient starts in Q3 2025 and a projected 225 or more by the end of 2025. The company estimates the disease population at 5,000 patients and reports a robust patient pipeline.
- Empaveli holds a unique position as the only approved product for pediatric and post-transplant C3G/IC-MPGN patients, where treatment urgency is notably higher. Increased adoption in the transplant population is anticipated throughout 2026 as it becomes a standard of care.
- The Syfovre market faced significant headwinds in 2025 due to a lack of foundation money for copay assistance, which disrupted retina practices and led to a pause in new geographic atrophy (GA) patient enrollments. However, practices are adapting to this new dynamic, and the company expects a new normalcy to emerge, with a focus on patients with advanced GA.
- Key tailwinds for Syfovre in 2026 and beyond include long-term GALE data demonstrating the potential to save 1.5 years of vision over five years of treatment, and the expected launch of prefilled syringes by late 2026, which is projected to significantly enhance adoption by streamlining clinic workflow.
- Syfovre maintains a dominant position in total prescriptions, with new prescriptions consistently in the mid-50% range compared to its competitor's 45%. The company is also advancing Abelast 3007 (RNAi) in Phase 1, aiming for every three-month subcutaneous dosing to improve treatment impact.
Dec 3, 2025, 7:10 PM
Apellis Discusses Empaveli Launch Progress and SYFOVRE Market Dynamics
APLS
Product Launch
New Projects/Investments
Demand Weakening
- Empaveli's launch for C3G and IC-MPGN is progressing as expected, with 152 new patient starts in Q3 and an anticipated 225 or more start forms by year-end. The company estimates the patient population at 5,000.
- SYFOVRE's market adoption has faced headwinds due to disruptions in foundation assistance for patient copays, which impacted retina practices' ability to enroll new geographic atrophy patients.
- Apellis anticipates that the introduction of prefilled syringes for SYFOVRE, expected towards the end of 2026, will significantly boost adoption by improving clinic workflow.
- Despite market challenges, SYFOVRE maintains a dominant position in total prescriptions, holding approximately mid-50% of new prescriptions compared to competitors.
- Apellis is also developing Abelast 3007 (RNAi), a subcutaneous injection aimed at enabling every three-month dosing for geographic atrophy and enhancing treatment impact.
Dec 3, 2025, 7:10 PM
Apellis Pharmaceuticals Provides Update on Empaveli Launch and Syfovre Performance
APLS
Product Launch
New Projects/Investments
Guidance Update
- Apellis Pharmaceuticals is nearing cash OpEx neutrality and holds over $450 million in cash, expressing confidence in achieving profitability based on its commercial products and expense profile.
- The company's drug, Empaveli, recently received approval for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN), demonstrating a 68% reduction in proteinuria in clinical trials. The launch is progressing well, with 225 start forms by the end of the first full quarter, representing 5% penetration of the estimated 5,000 US patient population.
- Syfovre, for geographic atrophy (GA), maintained its market leadership with over 60% market share overall and 55% on new injections in early 2025, despite a challenging 2025 for retina practices due to a lack of patient copay assistance, which resulted in approximately $40 million in free goods in the first three quarters of 2025. Long-term data indicates Syfovre can save about a year and a half worth of vision loss over five years.
- Apellis is advancing its pipeline with Phase 3 trials for Empaveli in FSGS (13,000 patients) and delayed graft function, and a registrational Phase 2 trial for an siRNA combo with Syfovre to potentially enable every three-month dosing and further slow GA progression. The company is also developing AI-powered technology to image and track functional decline in GA patients.
Dec 2, 2025, 7:30 PM
Quarterly earnings call transcripts for Apellis Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more